or
Home | About PUMC | Products | Business Development | News | Contact Us

Products

Pain Management

Gastroenterology

Nephrology

Oncology

Consumer Health


AD1

Product: AD1 injection
Indication: Treatment for various cancers
Status: Preclinical

AD1 is a novel Colchicine derivative, with Colchicine’s anti-tumor properties but with 150 times lower toxicity.

Colchicine

Colchicine is a toxic extract derived from Autumn Crocus and African Climbing Lily, of the genus Colchicum. Commonly prescribed as a treatment for acute gout, acute gouty arthritis, and familial Mediterranean fever, Colchicine’s anti-tumor properties are also well-documented.

Colchicine binds to tubulin and inhibits microtubule polymerization, preventing cancer cell mitosis. However, such so-called "colchicine poisoning" also affects normal cells, and can cause abdominal pain, nausea, vomiting, bone marrow depression, anorexia, and hepatotoxicity. Therefore, colchicine’s chemotherapeutic value is limited.

AD1

AD1, currently in preclinical development, is a novel Colchicine derivative that preserves Colchine’s efficacy against cancer cells, but with 150 times lower toxicity against normal cells.